An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma
NCT03227432
Withdrawn
This research study is studying a combination of targeted therapies as a possible treatment for multiple myeloma (MM). The drugs involved in this study are: * Elotuzumab * Nivolumab * Pomalidomide * Dexamethasone
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/10/2018
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Multiple Myeloma
Register for Updates
High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia
NCT00002865
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of high-intensity, brief-duration chemotherapy in treating patients with relapsed or refractory acute lymphocytic leukemia.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
08/08/2018
Locations: Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina
Conditions: Leukemia
Register for Updates
Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma
NCT01428492
Completed
Phase Ib, open-label study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and clinical activity of GSK2110183 dosed in combination with bortezomib and dexamethasone in multiple myeloma (MM) subjects who have failed at least one line of systemic treatment. Part 1 will identify the maximum tolerated dose(s) (MTD) of the combination regimen. Schedule A - GSK2110183 administered once daily with bortezomib (1.3 mg/m2) and dexamethasone (20 mg) given biweekly. Part... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2018
Locations: Novartis Investigative Site, Scottsdale, Arizona +12 locations
Conditions: Multiple Myeloma
Register for Updates
Systemic Steroids for Peripheral Nerve Blocks
NCT02464176
Completed
This study will investigate the ability of systemic dexamethasone to prolong the sensory block duration for lumbar plexus nerve blockade.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
07/31/2018
Locations: Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina
Conditions: Osteoarthritis, Hip
Register for Updates
Interscalene Block With Low-dose IV vs. Perineural Dexamethasone for Shoulder Arthroscopy
NCT02506660
Completed
Many patients undergoing ambulatory shoulder arthroscopy experience moderate to severe pain after surgery. Finding ways to minimize postoperative pain are ideal. Dexamethasone is a corticosteroid that is commonly used to prevent and/or treat nausea and inflammation. The addition of higher doses of dexamethasone to nerve blocks, which are injections of local anesthetics into the upper shoulder area, has been shown to prolong block duration and reduce pain. However, it is unclear whether the advan... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/31/2018
Locations: Hospital for Special Surgery, New York, New York
Conditions: Pain, Shoulder Arthroscopy
Register for Updates
Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis
NCT02517619
Completed
The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis.
Gender:
ALL
Ages:
Between 12 years and 85 years
Trial Updated:
07/24/2018
Locations: Virginia Eye Consultants, Norfolk, Virginia
Conditions: Anterior Uveitis
Register for Updates
Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery
NCT02547623
Completed
The study is a prospective, randomized, parallel-design, multicenter trial in patients ≥40 years of age undergoing cataract surgery. Patients who meet all inclusion and no exclusion criteria will be randomized to 1 of 2 treatment groups * A single 5 mcl anterior chamber injection of IBI 10090, 103.4 mcg/mcl dexamethasone, equivalent dexamethasone dose: 517 mcg at the conclusion of cataract surgery or; * Prednisolone acetate ophthalmic suspension 1% eye drops administered 1 drop 4 times daily (Q... Read More
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/24/2018
Locations: Kislinger MD inc, Glendora, California +10 locations
Conditions: Cataract
Register for Updates
Effect of Longer-term Adrenal Suppression Using Low Dose Hydrocortisone on Androgen Overproduction
NCT01422733
Withdrawn
This study will test whether longer-term suppression of adrenal function can ameliorate androgen (male hormone) overproduction in overweight early pubertal girls with androgen excess. The investigators hypothesize that suppression of nighttime adrenocorticotropin hormone (ACTH) production by 12 weeks of evening oral hydrocortisone administration will improve androgen levels in girls with adrenal androgen overproduction. Specifically, this intervention will improve androgen levels after adrenal s... Read More
Gender:
FEMALE
Ages:
Between 7 years and 16 years
Trial Updated:
07/17/2018
Locations: University of Virginia Center for Research in Reproduction, Charlottesville, Virginia
Conditions: Hyperandrogenemia, Obesity, Polycystic Ovary Syndrome
Register for Updates
Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors
NCT02071888
Completed
Many tumor cells, in contrast to normal cells, have been shown to require the amino acid glutamine to produce energy for growth and survival. To exploit the dependence of tumors on glutamine, CB-839, a potent and selective inhibitor of the first enzyme in glutamine utilization, glutaminase, will be tested in this Phase 1 study in patients with advanced hematologic malignancies. This study is an open-label Phase 1 evaluation of CB-839 in subjects with hematological tumors. Patients will receive... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2018
Locations: Mayo Clinic, Scottsdale, Arizona +6 locations
Conditions: Non-Hodgkin's Lymphoma (NHL), Multiple Myeloma, Waldenstrom's Macroglobulinemia (WM), Other B-cell NHL Subtypes, Including WM, T-cell NHL
Register for Updates
S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
NCT00064337
Completed
RATIONALE: Drugs used in chemotherapy such as melphalan work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with donor peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: This phase II trial is studying how well giving melphalan together with autologous stem cell transplantation works in treating patients with multiple myeloma or primary systemic amyloi... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
07/13/2018
Locations: Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas +34 locations
Conditions: Multiple Myeloma, Plasma Cell Myeloma
Register for Updates
S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT00124579
Terminated
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as thalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. It may also stop the growth of cancer by blocking blood flow to the cancer. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving b... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
07/13/2018
Locations: Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas +126 locations
Conditions: Multiple Myeloma
Register for Updates
Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel
NCT02491411
Terminated
This pilot trial studies how well dexamethasone and re-treatment with enzalutamide work in treating patients with prostate cancer that has spread to other places in the body (metastatic), does not respond to hormone therapy (hormone-resistant), and was previously treated with enzalutamide and docetaxel. Dexamethasone treatment may be able to reverse one resistance mechanism to enzalutamide therapy (overabundance of receptors for dexamethasone and other glucocorticoids inside cancer cells) and al... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/11/2018
Locations: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Conditions: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer
Register for Updates